Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
McKesson
McKinsey
Harvard Business School
Medtronic
Baxter
Argus Health
Citi

Generated: May 27, 2018

DrugPatentWatch Database Preview

HYDROCHLOROTHIAZIDE W/ RESERPINE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Hydrochlorothiazide W/ Reserpine, and when can generic versions of Hydrochlorothiazide W/ Reserpine launch?

Hydrochlorothiazide W/ Reserpine is a drug marketed by Ivax Sub Teva Pharms, Pharmeral, Roxane, and Watson Labs. and is included in fourteen NDAs.

The generic ingredient in HYDROCHLOROTHIAZIDE W/ RESERPINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for HYDROCHLOROTHIAZIDE W/ RESERPINE
Drug patent expirations by year for HYDROCHLOROTHIAZIDE W/ RESERPINE
Synonyms for HYDROCHLOROTHIAZIDE W/ RESERPINE
C33H40N2O9.C7H8ClN3O4S2
H.R.-50
HYDRO-SERP "25"
HYDRO-SERP "50"
HYDROCHLOROTHIAZIDE; RESERPINE
LS-178646
RESERPINE AND HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROCHLOROTHIAZIDE-50
SCHEMBL4265419

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W/ RESERPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ivax Sub Teva Pharms HYDROCHLOROTHIAZIDE W/ RESERPINE hydrochlorothiazide; reserpine TABLET;ORAL 083572-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roxane HYDROCHLOROTHIAZIDE W/ RESERPINE hydrochlorothiazide; reserpine TABLET;ORAL 084603-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ivax Sub Teva Pharms HYDROCHLOROTHIAZIDE W/ RESERPINE hydrochlorothiazide; reserpine TABLET;ORAL 083573-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Watson Labs HYDROCHLOROTHIAZIDE W/ RESERPINE hydrochlorothiazide; reserpine TABLET;ORAL 084467-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
Mallinckrodt
Queensland Health
US Department of Justice
Chubb
Citi
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.